| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CCR Practice of Translational Oncology |
Authors' Affiliations: Departments of 1 Gastrointestinal Medical Oncology, 2 Cancer Biology, and 3 Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Gary E. Gallick, Department of Cancer Biology, Box #173, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009. Phone: 713-563-4919; Fax: 713-563-5489; E-mail: ggallick{at}mdanderson.org.
Abstract
Aberrant activation of members of the Src family of nonreceptor protein tyrosine kinases is common in solid tumor malignancies and may contribute to the development and/or progression of these tumors. As a result, four Src inhibitors are now in more than 50 clinical trials for at least 14 different types of solid tumors. In this review, we briefly discuss the preclinical rationale for Src inhibitors, the development strategies most likely to be successful in the clinic, and the rationale for Src inhibitors in combination with other agents as part of a more comprehensive therapeutic strategy. As the use of Src family inhibitors in clinical trials on solid tumors is in its infancy, further studies on the roles of Src family kinases in tumor progression, chemoresistance, epidermal-to-mesenchymal transition, and other properties of tumor progression will be important in designing the most effective clinical trials using these inhibitors.
This article has been cited by other articles:
|
|
 |
|
  N.V. Rajeshkumar, A. C. Tan, E. De Oliveira, C. Womack, H. Wombwell, S. Morgan, M. V. Warren, J. Walker, T. P. Green, A. Jimeno, et al. Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer Clin. Cancer Res., June 15, 2009; 15(12): 4138 - 4146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Schweppe, A. A. Kerege, J. D. French, V. Sharma, R. L. Grzywa, and B. R. Haugen Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2199 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tatarov, T. J. Mitchell, M. Seywright, H. Y. Leung, V. G. Brunton, and J. Edwards Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3540 - 3549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kopetz, D. P. Lesslie, N. A. Dallas, S. I. Park, M. Johnson, N. U. Parikh, M. P. Kim, J. L. Abbruzzese, L. M. Ellis, J. Chandra, et al. Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress Cancer Res., May 1, 2009; 69(9): 3842 - 3849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, Y. Tu, J. Zhao, K. Chen, and C. Wu Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle J. Cell Biol., March 23, 2009; 184(6): 785 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J.J. Waugh and C. Wilson The Interleukin-8 Pathway in Cancer Clin. Cancer Res., November 1, 2008; 14(21): 6735 - 6741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Park, J. Zhang, K. A. Phillips, J. C. Araujo, A. M. Najjar, A. Y. Volgin, J. G. Gelovani, S.-J. Kim, Z. Wang, and G. E. Gallick Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model Cancer Res., May 1, 2008; 68(9): 3323 - 3333. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
